Lacosamide Eg

Lacosamide, the active ingredient in Lacosamide Eg, is an anti‑epileptic presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

- Partial‑onset seizures: reduces seizure frequency in patients with epilepsy. - Adjunct therapy in epilepsy: used alongside other antiepileptics to achieve better seizure control. - Secondary generalized seizures arising from focal onset: helps prevent progression of seizures.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Fatigue: feeling of reduced energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal ideation: emergence of thoughts of self‑harm. - Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Aseptic meningitis: rare inflammation of the meninges without infection.

Lacosamide should be used with caution in specific clinical situations. - Renal impairment: monitor renal function and adjust dose if necessary. - Hepatic impairment: assess liver function before initiating therapy. - Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk unknown; prescribe only if potential benefit outweighs risk. - Concomitant antiepileptic therapy: watch for additive CNS effects. - Store at ambient temperature: keep in original container, protect from moisture.

Lacosamide may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide efficacy. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): may increase risk of cardiac conduction issues.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): may alter plasma concentrations. - Alcohol: can enhance central nervous system depression. - CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide levels.